source
- Sanofi requests removal of teplizumab from FDA fast-track voucher program after director disputeSanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…
- Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipelineCentered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.